Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.
Please click here to read the abstract.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.